Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
Marian C Bryan1, Joy Drobnick1, Alberto Gobbi1
1Genentech, Inc. , One DNA Way , South San Francisco , California 94080 , United States.
Journal of Medicinal Chemistry
|May 15, 2019
Summary
Researchers developed novel dihydrobenzofuran inhibitors targeting Interleukin-1 receptor-associated kinase 4 (IRAK4) for inflammation. These compounds show improved drug-like properties, potent kinase inhibition, and efficacy in a mouse model, advancing IRAK4-targeted therapies.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Biochemistry
Background:
- Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator in inflammatory signaling pathways.
- Developing potent and selective IRAK4 inhibitors is crucial for treating inflammatory diseases.
Purpose of the Study:
- To discover and optimize novel inhibitors of IRAK4.
- To improve physicochemical properties for in vivo efficacy.
Main Methods:
- High-throughput screening (HTS) identified initial pyrazolopyrimidine hits.
- Structure-based drug design utilizing cocrystal and small-molecule crystal structures.
- Optimization of lead compounds to dihydrobenzofurans with improved druglike properties.
Main Results:
- Novel dihydrobenzofuran derivatives demonstrated high potency and kinase selectivity against IRAK4.
- Optimized compounds exhibited superior physicochemical properties, including enhanced solubility.
- Lead molecules showed low clearance and effective IRAK4 signaling inhibition in an inflammation mouse model.
Conclusions:
- Dihydrobenzofurans represent a promising scaffold for developing IRAK4 inhibitors.
- The optimized compounds possess favorable properties for further development in inflammatory disease therapeutics.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
01:32What is Natural Selection?
126.4K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
126.4K
00:57Antibiotic Selection
59.6K
Overview
59.6K
01:46Types of Selection
44.2K
Natural selection influences the frequencies of particular alleles and phenotypes within populations in several different ways. Primarily, natural selection can be directional, stabilizing, or disruptive. Directional selection favors one extreme trait and shifts the population towards that phenotype while selecting against individuals displaying alternate traits. Stabilizing selection favors an intermediate trait with a narrow range of variation. Deviation from the optimal phenotype towards an...
44.2K
01:21Frequency-dependent Selection
23.3K
When the fitness of a trait is influenced by how common it is (i.e., its frequency) relative to different traits within a population, this is referred to as frequency-dependent selection. Frequency-dependent selection may occur between species or within a single species. This type of selection can either be positive—with more common phenotypes having higher fitness—or negative, with rarer phenotypes conferring increased fitness.
23.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
618
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
618